ResMed Inc. (RMD)

Market Cap	40.78B
Revenue (ttm)	5.15B
Net Income (ttm)	1.40B
Shares Out	145.91M
EPS (ttm)	9.51
PE Ratio	29.39
Forward PE	25.71
Dividend	$2.40 (0.86%)
Ex-Dividend Date	Aug 14, 2025

Volume	688,429
Open	276.47
Previous Close	277.05
Day's Range	273.37 - 279.73
52-Week Range	199.92 - 293.81
Beta	0.85
Analysts	Buy
Price Target	276.82 (-0.94%)
Earnings Date	Oct 23, 2025

About RMD

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jun 2, 1995
• Employees: 9,980
• Stock Exchange: NYSE
• Ticker Symbol: RMD
• Website: https://www.resmed.co.in

Financial Performance

In 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.

Analyst Summary

According to 13 analysts, the average rating for RMD stock is "Buy." The 12-month stock price target is $276.82, which is a decrease of -0.94% from the latest price.

Price Target

$276.82

(-0.94% downside)

Analyst Consensus: Buy